FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| The Kansas City Cardiomyopathy Questionnaire in Relation to New York Heart Association Class. PMID 39349158 · J Card Fail · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Real-world outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial. PMID 39324506 · BJU Int · 2025-Feb The study reports real-world outcomes for patients screened for the BRAVO trial but does not present formal results of the randomized trial comparison. The trial phase is not specified as Phase III/IIIb or Phase II/III, and the results are not for the planned randomized intervention comparison. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase 3 Study. PMID 39300596 · Arthritis Rheumatol · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From a Randomized, Placebo-Controlled, Phase 3 Study. PMID 39300513 · Arthritis Rheumatol · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis. PMID 39293548 · Gastroenterology · 2025-Feb This is a phase 3 biomarker validation study for HCC detection in a diagnostic surveillance context. It is not a randomized trial and does not test a drug intervention or report time-to-event efficacy outcomes (e.g., OS, PFS). The primary endpoint is diagnostic performance (AUC, sensitivity, specificity). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Use of Water Sac Dilation in Resecting Parapharyngeal Space Benign Tumor via Transoral Approach. PMID 39289921 · Laryngoscope · 2025-Feb The record describes a randomized trial evaluating a surgical technique (water sac dilation) for a benign tumor. While oncology and human are true, and it is randomized with an original result, it lacks a drug-containing intervention and a time-to-event efficacy endpoint (OS, PFS, etc.), and the phase is not specified as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial. PMID 39261236 · Eur Urol Oncol · 2025-Feb 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Chemoradiotherapy plus immunotherapy for locoregionally advanced nasopharyngeal carcinoma: A cost-effectiveness analysis. PMID 39246032 · Head Neck · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes. PMID 39226189 · ESC Heart Fail · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of macitentan in Fontan-palliated patients: 52-week randomized, placebo-controlled RUBATO Phase 3 trial and open-label extension. PMID 39216715 · J Thorac Cardiovasc Surg · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia. PMID 39213466 · J Clin Oncol · 2025-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS). PMID 39213002 · Am J Respir Crit Care Med · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD. PMID 39197510 · Chest · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Association Between Baseline Macular Morphologic Features on Optical Coherence Tomography and Visual Outcomes in Patients with Vogt-Koyanagi-Harada Disease. PMID 39190826 · Ocul Immunol Inflamm · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis. PMID 39182898 · Clin Gastroenterol Hepatol · 2025-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| MERLIN: Two-Year Results of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. PMID 39182627 · Ophthalmology · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Disease Activity and Therapeutic Response to Pegcetacoplan for Geographic Atrophy Identified by Deep Learning-Based Analysis of OCT. PMID 39151755 · Ophthalmology · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial. PMID 39143002 · Eur Urol Oncol · 2025-Feb The study is a randomized, controlled trial of a drug (cabazitaxel) in oncology (prostate cancer) with time-to-event endpoints (time to pain progression, time to opiate use, time to deterioration of FACT-P). However, the primary analysis was safety/toxicity-focused (as per the main CABASTY study referenced). This publication is an original result report, but its primary objective and analysis focus on patient-reported pain and health-related quality of life (HRQoL), which is a secondary/key secondary endpoint, not the primary efficacy endpoint (e.g., OS, PFS) for this oncology trial. Therefore, it does not meet the inclusion criterion of having a primary/key secondary time-to-event efficacy endpoint as the main focus of the report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Rationale and Design for the BLOCK-SAH Study (Pterygopalatine Fossa Block as an Opioid-Sparing Treatment for Acute Headache in Aneurysmal Subarachnoid Hemorrhage): A Phase II, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial with a Sequential Parallel Comparison Design. PMID 39138719 · Neurocrit Care · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. PMID 39089633 · J Hepatol · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| First-line PARP inhibitor maintenance treatment in ovarian carcinoma for older adult women: a review of the current literature. PMID 39030437 · Clin Transl Oncol · 2025-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The Future of Clinical Trials in Inflammatory Bowel Disease. PMID 39025252 · Clin Gastroenterol Hepatol · 2025-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The efficacy and safety of a quadrivalent live attenuated influenza nasal vaccine in Japanese children: A phase 3, randomized, placebo-controlled study. PMID 38959995 · J Infect Chemother · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Multicenter clinical trial on functional evaluation of transoral laser microsurgery for supraglottic laryngeal carcinomas. PMID 38885651 · Laryngorhinootologie · 2025-Feb The record fails multiple key eligibility criteria: it is not randomized, lacks a drug-containing intervention, and is a protocol/design paper without reported results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial Protocol. PMID 38755095 · Eur Urol Oncol · 2025-Feb 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Patient-reported Quality of Life and Survival Outcomes in Prostate Cancer: Analysis of the ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED). PMID 38688766 · Eur Urol Oncol · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial. PMID 38584037 · Eur Urol Oncol · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Comparison of two techniques of goal directed fluid therapy in elective neurosurgical patients - a randomized controlled study. PMID 36734344 · Br J Neurosurg · 2025-Feb The study is a randomized controlled trial in human oncology patients, but it is not a Phase III/IIIb or definitive trial, lacks a drug intervention (comparing fluid therapy techniques), and does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). Primary and secondary endpoints are fluid volume, biochemical markers, and length of stay, not survival or time-to-event outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Novel Approach to Reducing Chemoresistance in Advanced Ovarian Cancer: The Effect of Itraconazole-A Single-Institution Randomized Placebo-Controlled Trial. PMID 41590341 · Curr Oncol · 2025-Dec-31 The record describes a randomized, placebo-controlled trial in advanced ovarian cancer with a drug intervention and reports progression-free survival (PFS) as a primary efficacy endpoint. However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the title, abstract, or provided metadata. Without explicit confirmation of the phase, the 'phase3_or_definitive' criterion cannot be met. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Erratum: Navigation of video-assisted thoracoscopic surgery using electromagnetic versus CT-guided localization (NOVEL): a study protocol for comparing procedural success and complication rates in a prospective, multicenter, randomized controlled, non-inferiority phase III trial. PMID 41510373 · Transl Lung Cancer Res · 2025-Dec-31 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Intranasal Bencycloquidium Bromide in Nasal Symptoms of Common Cold: a Phase 3, Multicenter, Randomised, Double-blind, Placebo-controlled Trial. PMID 41476148 · QJM · 2025-Dec-31 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Investigating the efficacy of electroacupuncture for postoperative ileus in patients with colorectal cancer: study protocol for a multicentre clinical trial with neuroimaging assessment. PMID 41475813 · BMJ Open · 2025-Dec-31 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| A surrogate endpoint-based provisional approval causal roadmap, illustrated by vaccine development. PMID 40544344 · Biostatistics · 2025-Dec-31 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Exposure proximal immune correlates analysis. PMID 39142660 · Biostatistics · 2025-Dec-31 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Disparities in Non-Small Cell Lung Cancer (NSCLC) by Age, Sex, and Race: A Systematic Review and Meta-Analysis of Immune Checkpoint Inhibitor (ICI) Trials. PMID 41514637 · Cancers (Basel) · 2025-Dec-30 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Radical antegrade modular pancreatosplenectomy versus conventional left pancreatectomy for pancreatic cancer: study protocol for the multicentre randomized clinical RAMPS trial. PMID 41649934 · BJS Open · 2025-Dec-29 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effect and Mechanisms of a Voice-based Coach using AI on Psychological Distress: A Phase 2 Randomized Trial. PMID 41503467 · medRxiv · 2025-Dec-29 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Two-fraction Ultrahypofractionated Radiotherapy with focal BOost for intermediate-risk, localized prostate cancer (TURBO): study protocol of a phase II, randomized controlled clinical trial. PMID 41466435 · Trials · 2025-Dec-29 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Intra-articular injection of umbilical cord-derived mesenchymal stem cells is safe and effective for moderate to severe knee osteoarthritis with synovitis: a double‑blinded and randomized controlled trial. PMID 41466394 · BMC Musculoskelet Disord · 2025-Dec-29 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Functional and cosmetic advantages of gasless endoscopic thyroidectomy in papillary thyroid carcinoma: a randomized trial. PMID 41466264 · World J Surg Oncol · 2025-Dec-29 The study is a randomized trial in human thyroid cancer but does not involve a drug-containing intervention and does not use a primary time-to-event efficacy endpoint. The primary endpoints are safety, lymph node counts, recurrence at 6 months, functional outcomes, and cosmetic satisfaction, which are not time-to-event efficacy measures like OS, PFS, or DFS. Additionally, the phase is not explicitly stated as Phase III or definitive. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized, non-inferiority phase III clinical trial of immunogenicity and safety of 5-dose and 4-dose schedules of a freeze-dried human rabies vaccine (MRC-5 cells) in participants aged 10-60. PMID 41466188 · BMC Infect Dis · 2025-Dec-29 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Lobectomy-first versus lymphadenectomy-first on long-term survival for operable non-small cell lung cancer: protocol of LOFTY trial. PMID 41462323 · Trials · 2025-Dec-29 This is a protocol for a randomized trial in oncology with a time-to-event primary endpoint (disease-free survival). However, it is not an original result report, is a non-drug-only (surgical) intervention, and the phase is not explicitly stated as Phase III or equivalent in the metadata. The trial registration and abstract indicate it is a protocol without results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanoma. PMID 41461960 · J Cancer Res Clin Oncol · 2025-Dec-29 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Comparison of the efficacy of TissuePatch™ versus no TissuePatch™ to seal pancreatic tissue surface for the prevention of pancreatic fistula after radical gastrectomy: study protocol for a prospective, single-center, randomized controlled trial. PMID 41456003 · Trials · 2025-Dec-28 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Phase III, multicenter, randomized, double-blind, placebo-controlled study of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease patients. PMID 41479524 · World J Hepatol · 2025-Dec-27 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201. PMID 41397917 · Oncologist · 2025-Dec-27 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 2 Figure · 2 Panel · risk unclear |
| Immunomodulatory Effects of Multivitamin Complexes Containing Agaricus blazei in Patients Undergoing Curative Resection for Non-Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Multicenter Pilot Trial. PMID 41595590 · Biomedicines · 2025-Dec-26 This is a randomized, double-blind, placebo-controlled pilot trial in NSCLC patients. However, it is not eligible because: 1) It is a pilot study, not explicitly Phase III or a definitive Phase II/III trial. 2) The intervention is a nutritional supplement (multivitamin complex), not a drug. 3) The primary endpoints are immunological and quality-of-life outcomes; no time-to-event efficacy endpoint (like OS or PFS) is reported or referenced. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized, controlled, multicenter phase III clinical trial of Huo Xiang Zheng Qi oral liquid for the prevention and control of nausea and vomiting caused by multiday cisplatin-based regimen. PMID 41466018 · Medicine (Baltimore) · 2025-Dec-26 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The effect of perioperative multimodal rehabilitation on the frailty state of older people patients with frailty gastrointestinal surgery: a randomized controlled trial. PMID 41454251 · BMC Geriatr · 2025-Dec-26 Eligible record must include a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). This study is a randomized controlled trial in oncology (gastrointestinal tumors) but evaluates a non-drug intervention (multimodal rehabilitation program) and reports frailty status, functional, and quality-of-life outcomes, not time-to-event efficacy endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Evaluating the role of mavacamten in symptomatic non-obstructive hypertrophic cardiomyopathy: the ODYSSEY-HCM trial. PMID 41449316 · Heart Fail Rev · 2025-Dec-26 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |